Analysts are on the Bearish side about Fibrocell Science, Inc. (NASDAQ:FCSC) this week.

January 21, 2018 - By Hazel Jackson

 Analysts are on the Bearish side about Fibrocell Science, Inc. (NASDAQ:FCSC) this week.

Fibrocell Science, Inc. (NASDAQ:FCSC) Ratings Coverage

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 10 analyst reports since September 28, 2015 according to SRatingsIntel. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) has “Buy” rating given on Tuesday, January 16 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 26. The firm earned “Buy” rating on Tuesday, December 22 by TH Capital. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) earned “Buy” rating by H.C. Wainwright on Wednesday, August 9. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) has “Neutral” rating given on Monday, September 28 by Wedbush. The firm has “Buy” rating by Roth Capital given on Tuesday, December 22. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) earned “Buy” rating by H.C. Wainwright on Thursday, October 5. The firm earned “Buy” rating on Friday, June 9 by H.C. Wainwright. Below is a list of Fibrocell Science, Inc. (NASDAQ:FCSC) latest ratings and price target changes.

16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.6 Maintain
26/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.6 Maintain
11/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.7000 Maintain

The stock decreased 3.34% or $0.0249 during the last trading session, reaching $0.7201. About 385,528 shares traded. Fibrocell Science, Inc. (NASDAQ:FCSC) has declined 57.80% since January 21, 2017 and is downtrending. It has underperformed by 74.50% the S&P500.

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $10.60 million. The companyÂ’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.

More news for Fibrocell Science, Inc. (NASDAQ:FCSC) were recently published by: Prnewswire.com, which released: “Technical Perspectives on Generic Drugs Stocks — Fibrocell Science, Galectin …” on January 19, 2018. Streetinsider.com‘s article titled: “Form 8-K Fibrocell Science, Inc. For: Dec 29” and published on December 29, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.